ヘリコバクターピロリ菌ワクチンの世界市場機会分析...市場調査レポートについてご紹介

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV065_TOC_151130.pdf

****This product is composed of two forecast models and a summary presentation

Title page
Author’s note
Contents
Executive summary
H.pylori prophylatic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori prophylatic vaccine: volumes per scenario to 2035 (000s)
H.pylori prophylatic vaccine: revenues – China and Japan ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues per scenario to 2035 ($ 000s)
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) new cases
H.pylori therapeutic vaccine: revenues to 2035 ($ 000s) ever cases
H.pylori: Epidemiology and general disease background
The pathogen
H.pylori: epidemiologic burden
H.pylori: epidemiologic burden (Western countries)
United States: seroprevalence of H.pylori
H.pylori: global prevalence map
H.pylori – trends in epidemiology
What is the outcome of H.pylori infection?
What is the outcome of H.pylori infection?
Natural history of H.pylori infection
H.pylori – molecular pathogenesis
H.pylori – mechanism of tumorigenesis
Diagnosis of H.pylori infection
H.pylori and gastric cancer: general background
Gastric Cancer Estimated Incidence, Worldwide in 2012: Men
Gastric cancer: incidence rates per top 20 countries, 2012
Gastric cancer: focus countries – China and Japan
Trends in incidence of stomach cancer in selected countries: age-standardised rate per 100,000, men
H.pylori and non cardia gastric cancer and CagA strains
Global distribution of cag pathogenicity island
Major outcome: peptic ulcer disease
Peptic ulcer disease and H.pylori infection
Diagnosis of H.pylori infection
Indications for H.pylori treatment
Treatment of H.pylori infection
First-Line Regimens for H.pylori eradication
H.pylori treatment: understanding patient flow (PUD)
H.pylori and antibiotic resistance, other factors
H.pylori and antibiotic resistance (developing world)
Economic burden of Gastrointestinal diseases
Peptic ulcer disease: pharmaceuticals market value (2017)
H.pylori eradication therapy: global market value 2005
H.pylori – other disease outcomes
H.pylori vaccine development
History of R&D approaches and current status
The medical need for a H.pylori vaccine
Notable challenges to H.pylori vaccine development
History of H.pylori vaccine development (preclinical)
Potential H.pylori vaccine antigens (preclinical studies)
H.pylori vaccines: past human studies
Clinical trials for vaccine efficacy against H.pylori: summary
H.pylori vaccine: Chinese study – Chong Qing Kang Wei (CQKW)
H.pylori vaccine (CQKW): – Phase III data
CQKW vaccine – a major advance?
CQKW vaccine: potential obstacles for Western use
CQKW vaccine – current status
H.pylori vaccines – other R&D approaches (ImevaX GmbH)
H.pylori vaccines – other R&D approaches (AMRIC – Canada)
H.pylori vaccines – other R&D approaches (EpiVax)
The cost effectiveness of a H.pylori vaccine
H.pylori vaccines: modelling commercial potential
Broad target populations for a H.pylori vaccine (PX & TX)
Drivers and resistors to prophylatic vaccine (PX)
Drivers and resistors to therapeutic vaccine (TX)
H.pylori vaccines: Target Product Profiles (TPPs)
Modelling methodology: prophylatic vaccine (PX)
PX vaccine: hypothetical launch sequence
PX vaccine: hypothetical launch sequence: LO scenario
PX vaccine: hypothetical launch sequence: Base scenario
PX vaccine: hypothetical launch sequence: HI scenario
PX vaccine: predicted vaccine coverage (< 1yrs) PX vaccine: predicted vaccine coverage (preadolescence) PX vaccine: pricing estimates – guiding assumptions PX vaccine: pricing estimates – summary H.pylori therapeutic vaccine (PX): vaccine positioning Modelling methodology: therapeutic vaccine (TX) Peptic ulcer disease patient segmentation Modelling new PUD cases (TX vaccine) Modelling recurrent ever cases (TX vaccine) TX vaccine: other modelling assumptions TX vaccine: potential upsides Bibliography